Studio clinico sull'attività antiinfiammatoria e sulla tollerabilità gastro-enterica di amtolmètineguacil, un nuovo FANS, in confronta a diclofenac su pazienti anziani con patologie osteoarticolari

Translated title of the contribution: Clinical study of the antinflammatory activity and gastroenteric tolerability of amtolmetin guacyl, a new nsaid, in comparison with diclofenac in elderly osteoarthritic patients

Antonino Tavella, Giuseppe Ursini

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The study was conducted in a cohort of 50 female patients, all in the active phase of various osteoarthritic diseases. All had a documented past history of gastric distress requiring pre- and post-treatment endoscopic monitoring. The 50 subjects were divided randomly into two 25-patient groups. One group received amtolmetin guacyl (1200 mg/day orally in two daily administrations on an empty stomach for the first three days of treatment and 600 mg/day once daily on an empty stomach for the remaining 27 days) and the other received diclofenac (150 mg/day orally in three daily administrations on a full stomach for the duration of the treatment period). The statistical significances of the antiphlogistic activity of the two drugs were very close to one another. The gastric tolerability verified at T0 and T30 through endoscopic monitoring of the mucosal conditions was excellent for Artromed (slight improvement after 30 days) and critical for diclofenac (significant (P≤0.01) deterioration after 30 days). All of the patients in the Artromed group terminated the period of therapy whilst 3 patients from the diclofenac group were obliged to abandon the study through accumulation of undesirable side-effects (12%).

Original languageItalian
Pages (from-to)543-548
Number of pages6
JournalClinica Terapeutica
Volume148
Issue number11
Publication statusPublished - Nov 1997

Fingerprint

Diclofenac
Stomach
Therapeutics
Clinical Studies
ST 679
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{03f72136dbd24a85a10267e011381c49,
title = "Studio clinico sull'attivit{\`a} antiinfiammatoria e sulla tollerabilit{\`a} gastro-enterica di amtolm{\`e}tineguacil, un nuovo FANS, in confronta a diclofenac su pazienti anziani con patologie osteoarticolari",
abstract = "The study was conducted in a cohort of 50 female patients, all in the active phase of various osteoarthritic diseases. All had a documented past history of gastric distress requiring pre- and post-treatment endoscopic monitoring. The 50 subjects were divided randomly into two 25-patient groups. One group received amtolmetin guacyl (1200 mg/day orally in two daily administrations on an empty stomach for the first three days of treatment and 600 mg/day once daily on an empty stomach for the remaining 27 days) and the other received diclofenac (150 mg/day orally in three daily administrations on a full stomach for the duration of the treatment period). The statistical significances of the antiphlogistic activity of the two drugs were very close to one another. The gastric tolerability verified at T0 and T30 through endoscopic monitoring of the mucosal conditions was excellent for Artromed (slight improvement after 30 days) and critical for diclofenac (significant (P≤0.01) deterioration after 30 days). All of the patients in the Artromed group terminated the period of therapy whilst 3 patients from the diclofenac group were obliged to abandon the study through accumulation of undesirable side-effects (12{\%}).",
keywords = "Amtolm{\`e}tineguacil, Diclofenac, Gastroscopia",
author = "Antonino Tavella and Giuseppe Ursini",
year = "1997",
month = "11",
language = "Italian",
volume = "148",
pages = "543--548",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "11",

}

TY - JOUR

T1 - Studio clinico sull'attività antiinfiammatoria e sulla tollerabilità gastro-enterica di amtolmètineguacil, un nuovo FANS, in confronta a diclofenac su pazienti anziani con patologie osteoarticolari

AU - Tavella, Antonino

AU - Ursini, Giuseppe

PY - 1997/11

Y1 - 1997/11

N2 - The study was conducted in a cohort of 50 female patients, all in the active phase of various osteoarthritic diseases. All had a documented past history of gastric distress requiring pre- and post-treatment endoscopic monitoring. The 50 subjects were divided randomly into two 25-patient groups. One group received amtolmetin guacyl (1200 mg/day orally in two daily administrations on an empty stomach for the first three days of treatment and 600 mg/day once daily on an empty stomach for the remaining 27 days) and the other received diclofenac (150 mg/day orally in three daily administrations on a full stomach for the duration of the treatment period). The statistical significances of the antiphlogistic activity of the two drugs were very close to one another. The gastric tolerability verified at T0 and T30 through endoscopic monitoring of the mucosal conditions was excellent for Artromed (slight improvement after 30 days) and critical for diclofenac (significant (P≤0.01) deterioration after 30 days). All of the patients in the Artromed group terminated the period of therapy whilst 3 patients from the diclofenac group were obliged to abandon the study through accumulation of undesirable side-effects (12%).

AB - The study was conducted in a cohort of 50 female patients, all in the active phase of various osteoarthritic diseases. All had a documented past history of gastric distress requiring pre- and post-treatment endoscopic monitoring. The 50 subjects were divided randomly into two 25-patient groups. One group received amtolmetin guacyl (1200 mg/day orally in two daily administrations on an empty stomach for the first three days of treatment and 600 mg/day once daily on an empty stomach for the remaining 27 days) and the other received diclofenac (150 mg/day orally in three daily administrations on a full stomach for the duration of the treatment period). The statistical significances of the antiphlogistic activity of the two drugs were very close to one another. The gastric tolerability verified at T0 and T30 through endoscopic monitoring of the mucosal conditions was excellent for Artromed (slight improvement after 30 days) and critical for diclofenac (significant (P≤0.01) deterioration after 30 days). All of the patients in the Artromed group terminated the period of therapy whilst 3 patients from the diclofenac group were obliged to abandon the study through accumulation of undesirable side-effects (12%).

KW - Amtolmètineguacil

KW - Diclofenac

KW - Gastroscopia

UR - http://www.scopus.com/inward/record.url?scp=0031262539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031262539&partnerID=8YFLogxK

M3 - Articolo

C2 - 9494257

AN - SCOPUS:0031262539

VL - 148

SP - 543

EP - 548

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 11

ER -